"The U.S. Food and Drug Administration today approved Aptiom (eslicarbazepine acetate) as an add-on medication to treat seizures associated with epilepsy.
Epilepsy is a brain disorder caused by abnormal or excessive activity in the brain"...
Tridione Side Effects Center
Medical Editor: John P. Cunha, DO, FACOEP
Tridione (trimethadione) is a seizure medication (antiepileptic) used to control absence ("petit mal") seizures. Common side effects include mild dizziness, poor coordination, drowsiness, blurred or double vision, or irregular back-and-forth movements of the eyes, decreased appetite, nausea, or vomiting, or increased sensitivity of the skin to sunlight.
The usual adult dosage of Tridione is 0.9-2.4 grams daily in 3 or 4 equally divided doses (i.e., 300-600 mg 3 or 4 times daily). Tridione may interact with other drugs that cause drowsiness, including antidepressants, alcohol, antihistamines, pain relievers, anxiety medicines, other seizure medicines, and muscle relaxants. Tell your doctor all medications and supplements you use. Tridione is known to be harmful to a fetus. Malformations of the face and head, heart, and nervous system have been reported. Tell your doctor if you are pregnant or could become pregnant during treatment. It is unknown if Tridion passes into breast milk and how it might affect a nursing infant. Consult your doctor before breastfeeding.
Our Tridione (trimethadione) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
What is Prescribing information?
The FDA package insert formatted in easy-to-find categories for health professionals and clinicians.
Tridione FDA Prescribing Information: Side Effects
The following side effects, some of them serious, have been associated with the use of TRIDIONE (trimethadione).
Drowsiness usually subsides with continued therapy. If it persists, a reduction in dosage is indicated.
Bleeding gums, epistaxis, retinal and petechial hemorrhages, vaginal bleeding, neutropenia, leukopenia, eosinophilia, thrombocytopenia, pancytopenia, agranulocytosis, hypoplastic anemia, and fatal aplastic anemia.
Fatal nephrosis has occurred.
Hepatitis has been reported rarely.
A myasthenia gravis-like syndrome has been reported.
Read the entire FDA prescribing information for Tridione (Trimethadione Tablets) »
Additional Tridione Information
Report Problems to the Food and Drug Administration
Find tips and treatments to control seizures.